Intrathecal Administration of Oxytocin Induces Analgesia in Low Back Pain Involving the Endogenous Opiate Peptide System

Publisher Website
Google Scholar
Abstract
The effect of oxytocin on low back pain in patients and its mechanism in rats were investigated. Intrathecal injection, radioimmunoassay, and potassium lontophoresis tail-flick test were used to investigate the effect of oxytocin. In humans, acute and chronic low back pain causes a marked change of oxytocin content within cerebral spinal fluid and plasma: oxytocin relieves low back pain (ED50 0.172 in chronic and 0.121 μg/kg in acute). In rats, oxytocin had a dose-related analgesic effect (ED50 0.067 μg/kg). At high levels, oxytocin induced locomotor ataxia (ED50 17.915 μg/kg) and death (LD50 27.224 μg/kg). Oxytocin antagonist [d(CH2)5, Tyr(Me)2, OrnF]-vasotocin and opiate receptor-blocker naloxone could reverse oxytocin-induced analgesia. Oxytocin also increased beta-endorphin, L-encephalin, and dynorphin A1–12 contents in the spinal cord, whereas oxytocin antagonist caused a decrease. These results suggest that oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system and may be effective and safe in acute and chronic low back pain.

This publication has 0 references indexed in Scilit: